Development of FABP3 ligands that inhibit arachidonic acid-induced α-synuclein oligomerization

•αSyn oligomerization is facilitated by FABP3 expression and AA treatment.•Highly selective FABP3 ligands can be developed using the ANS assay.•The selective FABP3 ligands inhibit AA-induced αSyn oligomerization. In Parkinson’s disease (PD), α-synuclein (αSyn) accumulation and inclusion triggers dop...

Full description

Saved in:
Bibliographic Details
Published in:Brain research 2019-03, Vol.1707, p.190-197
Main Authors: Cheng, An, Shinoda, Yasuharu, Yamamoto, Tetsunori, Miyachi, Hiroyuki, Fukunaga, Kohji
Format: Article
Language:English
Subjects:
Arachidonic acid
FABP ligands
FABP3
Parkinson’s disease
αSyn oligomerization
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•αSyn oligomerization is facilitated by FABP3 expression and AA treatment.•Highly selective FABP3 ligands can be developed using the ANS assay.•The selective FABP3 ligands inhibit AA-induced αSyn oligomerization. In Parkinson’s disease (PD), α-synuclein (αSyn) accumulation and inclusion triggers dopamine neuronal death and synapse dysfunction in vivo. We previously reported that fatty acid-binding protein 3 (FABP3) is highly expressed in the brain and accelerates αSyn oligomerization when cells are exposed to 1-Methyl-1,2,3,6-tetrahydropiridine (MPTP). Here, we demonstrate that αSyn oligomerization was markedly enhanced by co-overexpressing FABP3 in neuro-2A cells when cells were treated with arachidonic acid (AA). We developed FABP3 ligands, which bind to the fatty acid binding domain of FABP3, using an 8-Anilinonaphthalene-1-sulfonic acid (ANS) assay with a recombinant FABP3 protein. The prototype for the FABP4 ligand, BMS309403, has no affinity for FABP3. We developed more FABP3-specific ligands derived from the chemical structure of BMS309403. Like AA, ligands 1, 7, and 8 had a relatively high affinity for FAPB3 in the ANS assay. Then, we evaluated the inhibition of αSyn oligomerization in neuro-2A cells co-overexpressing FABP3 and αSyn. Importantly, AA treatments markedly enhanced αSyn oligomerization in the co-expressing cells. Ligands 1, 7, and 8 significantly reduced AA-induced αSyn oligomerization in neuro-2A cells. Taken together, our results indicate that FABP3 ligands that target FABP3 may be used as potential therapeutics that inhibit αSyn aggregation in vivo.
ISSN:0006-8993
1872-6240
DOI:10.1016/j.brainres.2018.11.036